Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China

Acta Pharmacologica Sinica

Volumn 33, Issue 12, 2012, Pages 1563-1570

  Meng, Xiang Guang ^a   Guo, Cheng Xian ^a   Feng, Guo Qing ^b   Zhao, Ying Chun ^c   Zhou, Bo Ting ^a,d   Han, Jian Le ^e   Chen, Xin ^e   Shi, Yong ^e   Shi, Hong Yao ^a   Yin, Ji Ye ^a   Peng, Xiang Dong ^a   Pei, Qi ^a   Zhang, Wei ^a   Wang, Guo ^a   He, Meng ^b   Liu, Min ^b   Yang, Jing Ke ^f   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e Department of Organ Transplantation   (China)

^f Henan Cancer Hospital   (China)

Author keywords

ABCB1; Cyclosporine A; CYP3A; Gene polymorphism; Pharmacogenetics; Pharmacokinetics; Renal transplantation

Indexed keywords

CREATININE; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HEMOGLOBIN; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; UREA;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENZYME POLYMORPHISM; EVENING DOSAGE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HEMOGLOBIN BLOOD LEVEL; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84870778571     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.136     Document Type: Article

References (35)

1. Colombo D, Ammirati E. Cyclosporine in transplantation-a historyof converging timelines. J Biol Regul Homeost Agents 2011; 25:493-504
2. Masuda S, Inui K. An up-date review on individualized dosageadjustment of calcineurin inhibitors in organ transplant patients.Pharmacol Ther 2006; 112: 184-98
3. Garcia-Saiz M, Lopez-Gil A, Alfonso I, Boada JN, Armijo JA. Factorsinfluencing cyclosporine blood concentration-dose ratio. AnnPharmacother 2002; 36: 193-9
4. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, et al.CYP3A5 genetic polymorphisms in different ethnic populations. DrugMetab Dispos 2005; 33: 884-7
5. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequencediversity in CYP3A promoters and characterization of the genetic basisof polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91
6. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Tu JH, Wang D, et al. Effects of geneticpolymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporinepharmacokinetics after renal transplantation. Clin Exp PharmacolPhysiol 2006; 33: 1093-8
7. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, et al. Associationof MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms withcyclosporine pharmacokinetics in Chinese renal transplant recipients.Eur J Clin Pharmacol 2008; 64: 1069-84
8. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA,de Fijter JW, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1are not associated with cyclosporine pharmacokinetics nor withcyclosporine clinical end points after renal transplantation. Ther DrugMonit 2011; 33: 178-84
9. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, GroppaliE, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1single nucleotide polymorphisms in Italian teenagers after kidneytransplantation. Pharmacol Rep 2010; 62: 1159-69
10. Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Associationof ABCB1, CYP3A4*18B and CYP3A53 genotypes with thepharmacokinetics of tacrolimus in healthy Chinese subjects: apopulation pharmacokinetic analysis. J Clin Pharm Ther 2011; 36:614-24
11. Zeng Y, He YJ, He FY, Fan L, Zhou HH. Effect of bifendate on thepharmacokinetics of cyclosporine in relation to the CYP3A418Bgenotype in healthy subjects. Acta Pharmacol Sin 2009; 30: 478-84
12. Qiu F, He XJ, Sun YX, Li-Ling J, Zhao LM. Influence of ABCB1,CYP3A418B and CYP3A53 polymorphisms on cyclosporine Apharmacokinetics in bone marrow transplant recipients. PharmacolRep 2011; 63: 815-25
13. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M,Nakamura T, et al. Haplotypes of CYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population. Hum Mutat 2004; 23:100
14. Haufroid V. Genetic polymorphisms of ATP-binding cassettetransporters ABCB1 and ABCC2 and their impact on drug disposition.Curr Drug Targets 2011; 12: 631-46
15. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, StruchinerCJ, Ojopi EB, et al. Pharmacogenetics of calcineurin inhibitors inBrazilian renal transplant patients. Pharmacogenomics 2011; 12:1293-303
16. Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B,Behzadi S, Malekhoseinie SA, et al. Association between cyclosporineconcentration and genetic polymorphisms of CYP3A5 and MDR1during the early stage after renal transplantation. Exp Clin Transplant2006; 4: 416-9
17. Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, et al. Effect of geneticpolymorphisms of CYP3A5 and MDR1 on cyclosporine concentrationduring the early stage after renal transplantation in Chinese patientsco-treated with diltiazem. Eur J Clin Pharmacol 2009; 65: 239-47
18. Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose,trough level, and relative clearance of tacrolimus in renal transplantrecipients. Transplant Proc 2000; 32: 1689-92
19. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 singlenucleotide polymorphisms on the pharmacokinetics and pharmacodynamicsof calcineurin inhibitors: Part I. Clin Pharmacokinet2010; 49: 141-75
20. Chu XM, Hao HP, Wang GJ, Guo LQ, Min PQ. Influence of CYP3A5genetic polymorphism on cyclosporine A metabolism and eliminationin Chinese renal transplant recipients. Acta Pharmacol Sin 2006; 27:1504-8
21. Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, Si-Tu B, et al. Tacrolimusdosing in Chinese renal transplant recipients: a population- basedpharmacogenetics study. Eur J Clin Pharmacol 2011; 67: 787-95
22. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contributionto variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev2002; 54: 1271-94
23. Tang HL, Ma LL, Xie HG, Zhang T, Hu YF. Effects of the CYP3A53variant on cyclosporine exposure and acute rejection rate in renaltransplant patients: a meta-analysis. Pharmacogenet Genomics2010; 20: 525-31
24. Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, etal. Impact of the CYP3A4*1G polymorphism and its combinationwith CYP3A5 genotypes on tacrolimus pharmacokinetics in renaltransplant patients. Pharmacogenomics 2011; 12: 977-84
25. Cheung CY, Op den Buijsch RA, Wong KM, Chan HW, Chau KF, Li CS,et al. Influence of different allelic variants of the CYP3A and ABCB1genes on the tacrolimus pharmacokinetic profile of Chinese renaltransplant recipients. Pharmacogenomics 2006; 7: 563-74
26. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al.Frequency of single nucleotide polymorphisms in the P-glycoproteindrug transporter MDR1 gene in white subjects. Clin Pharmacol Ther2001; 69: 169-74
27. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al.Identification of functionally variant MDR1 alleles among EuropeanAmericans and African Americans. Clin Pharmacol Ther 2001; 70:189-99
28. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M,Johns SJ, et al. Sequence diversity and haplotype structure in thehuman ABCB1 (MDR1, multidrug resistance transporter) gene.Pharmacogenetics 2003; 13: 481-94
29. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, ViklickyO. Haplotypic structure of ABCB1/MDR1 gene modifies the risk ofthe acute allograft rejection in renal transplant recipients. Transplantation2008; 86: 1206-13
30. Hermann M, Enseleit F, Fisler AE, Flammer A, Luscher TF, Noll G,et al. Cyclosporine C0-versus C2-monitoring over three years inmaintenance heart transplantation. Swiss Med Wkly 2011; 141:w13149
31. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-levelmonitoring: a systematic review. Transplantation 2007; 83: 1525-35
32. Sommerer C, Schnitzler P, Meuer S, Zeier M, Giese T. Pharmacodynamicmonitoring of cyclosporin A reveals risk of opportunisticinfections and malignancies in renal transplant recipients 65 yearsand older. Ther Drug Monit 2011; 33: 694-8
33. Zhu H, Ge W. Future of the pharmacogenomics of calcineurininhibitors in renal transplant patients. Pharmacogenomics 2011; 12:1505-8
34. El-Sankary W, Plant NJ, Gibson GG, Moore DJ. Regulation ofthe CYP3A4 gene by hydrocortisone and xenobiotics: role of theglucocorticoid and pregnane X receptors. Drug Metab Dispos 2000;28: 493-6
35. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A,Munteanu E, et al. Donor P-gp polymorphisms strongly influencerenal function and graft loss in a cohort of renal transplant recipientson cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther2010; 88: 95-100.